Capricorn Products Overview

  • Founded
  • 1994
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Capricorn Products General Information


Manufacturer and supplier of bulk immunodiagnostic raw materials created to be used in immunochemistry and infectious disease testing. The company's product lines include goat polyclonal antisera for turbidimetric and nephelometric serum protein assays, standard and custom calibrators and controls, OEM reagents manufactured to customer specifications, and an extensive range of monoclonal and polyclonal antibodies and antigens used in immunochemistry and infectious disease testing, enabling biotechnologists to selectively distribute unique antibodies and antigens for its customers.

Contact Information

Ownership Status
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Other Pharmaceuticals and Biotechnology
Other Chemicals and Gases
Parent Company
Primary Office
  • 12 Rice Street
  • Portland, ME 04103
  • United States
+1 (207) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Capricorn Products Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Merger/Acquisition 25-Jul-2019 Completed Generating Revenue
2. Undetermined 01-Jan-2003 Completed Product Development
1. Early Stage VC 01-Jan-1998 Completed Product Development
To view Capricorn Products’s complete valuation and funding history, request access »

Capricorn Products Executive Team (2)

Name Title Board Seat Contact Info
Jane Havey Founder, President & Chief Executive Officer
Cynthia Leonard Director
To view Capricorn Products’s complete executive team members history, request access »

Capricorn Products Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Maine Venture Fund Venture Capital Minority 000 0000 000000 0
To view Capricorn Products’s complete investors history, request access »